Address
Email address
Phone number
Website
https://tbdpharmatech.com/TBD Pharmatech – Contract Development and ManufacturingTBD Pharmatech specialises in Active Pharmaceutical Ingredients, advanced intermediates, and the development and production of fine chemicals
Name
osaühing TBD Pharmatech
Registry code
11204964
VAT number
EE101057350
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
10.02.2006 (19)
Financial year
01.01-31.12
Capital
7 136.00 €
Activity
46711 - Wholesale of solid fuels 21101 - Manufacture of basic pharmaceutical products
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| KemInvent OÜ 12771636 | 70% - 4 995.00 EUR | - | - | |
| Andrus Tasa
| - | Board member | - | |
| Tõnis Tasa
| - | Board member | - | |
| aktsiaselts Biotehnoloogia Park Kinnisvara 10834232 | - | - | - | Founder |
| Ago Rinken
| - | - | - | Founder |
| Allan Nurk
| - | - | - | Founder |
| Margus Pooga
| - | - | - | Founder |
| Uno Mäeorg
| - | - | - | Founder |
| Ursel Soomets
| - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Celvia CC AS 11673707 | - | - | - | Founder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 1 172 092.42 € | - | 225 063.01 € | 59 |
| 2024 Q3 | 1 789 465.44 € | 68 805.5 € | 228 729.45 € | 57 |
| 2024 Q2 | 1 517 828.93 € | 224 216.1 € | 240 261.12 € | 58 |
| 2024 Q1 | 1 685 144.16 € | 225 221.26 € | 236 776.97 € | 63 |
| 2023 Q4 | 971 856.71 € | 201 862.88 € | 213 991.02 € | 60 |
| 2023 Q3 | 699 168.68 € | 227 222.28 € | 239 670.3 € | 60 |
| 2023 Q2 | 1 614 405.79 € | 186 006.49 € | 199 986.44 € | 61 |
| 2023 Q1 | 1 166 585.21 € | 202 565.31 € | 216 919.14 € | 64 |
| 2022 Q4 | 1 622 264.28 € | 174 586.86 € | 187 465.18 € | 70 |
| 2022 Q3 | 1 558 499.38 € | 180 642.65 € | 194 184.7 € | 65 |
| 2022 Q2 | 803 903.73 € | 160 191.15 € | 171 975.68 € | 61 |
| 2022 Q1 | 1 696 525.74 € | 160 988.43 € | 172 621.89 € | 57 |
| 2021 Q4 | 1 434 646.04 € | 126 205.42 € | 133 696.27 € | 60 |
| 2021 Q3 | 1 378 461.41 € | 147 704.27 € | 158 985.11 € | 55 |
| 2021 Q2 | 1 421 441.74 € | 132 915.2 € | 142 967.5 € | 59 |
| 2021 Q1 | 1 074 740.78 € | 134 266.22 € | 144 253.75 € | 55 |
| 2020 Q4 | 1 217 763.87 € | 122 068.65 € | 130 788.06 € | 50 |
| 2020 Q3 | 1 151 313.51 € | 117 678.63 € | 126 209.44 € | 47 |
| 2020 Q2 | 1 934 858.61 € | 106 476.75 € | 114 368.62 € | 42 |
| 2020 Q1 | 850 156.14 € | 107 868.18 € | 115 850.46 € | 40 |
